REG - IQ-AI Limited - IB Opens Expanded Access Program

IQ-AIAnnouncement

25/06/2024 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240625:nRSY7858Ta&default-theme=true

RNS Number : 7858T  IQ-AI Limited  25 June 2024

June 25, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics Opens Expanded Access Program

New cancer treatment with the potential to slow brain tumor growth is now
available to patients in the US with relapsed/refractory histologic or
molecular glioblastoma

Imaging Biometrics, LLC ("IB"), the Wisconsin USA based subsidiary of IQ-AI
(LSE: IQAI), announces that the US Food and Drug Administration ("FDA") has
approved an Expanded Access Program ("EAP") for oral gallium maltolate
("GaM").

This EAP will run in parallel with the current phase 1 clinical trial being
conducted at the Medical College of Wisconsin ("MCW"). As the phase 1 trial
concludes this fall and while the data is being compiled, eligible patients in
the US will have the option of participating in the EAP. Several patients have
registered to participate in the EAP, and a total of 40 patients can enrol in
this initial phase.

"Providing eligible patients access to GaM as a potential treatment ahead of
regulatory approval underscores our commitment to helping address a clear
unmet patient need," said Trevor Brown, CEO of IQAI.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRVELBLZQLEBBQ